

Clinical Policy: Histrelin Acetate (Vantas, Supprelin LA)

Reference Number: CP.PHAR.172

Effective Date: 10.01.16

Last Review Date: 11.22

Line of Business: Medicaid, HIM-Medical Benefit

[Coding Implications](#)[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Histrelin acetate (Vantas[®] and Supprelin LA[®]) is a gonadotropin-releasing hormone (GnRH) agonist.

FDA Approved Indication(s)

Vantas is indicated for the palliative treatment of advanced prostate cancer.

Supprelin LA is indicated for the treatment of children with central precocious puberty (CPP).

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation[®] that Vantas and Supprelin LA are **medically necessary** when the following criteria are met:

I. Initial Approval Criteria**A. Prostate Cancer** (must meet all):

1. Diagnosis of prostate cancer;
2. Request is for Vantas;
3. Prescribed by or in consultation with an oncologist or urologist;
4. Age \geq 18 years;
5. Request meets one of the following (a or b):*
 - a. Dose does not exceed 50 mg per 12 months (one implant per year);
 - b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Prescribed regimen must be FDA-approved or recommended by NCCN*

Approval duration: 12 months

B. Central Precocious Puberty (must meet all):

1. Diagnosis of CPP confirmed by all of the following (a, b, and c):
 - a. Elevated basal luteinizing hormone (LH) level $> 0.2 - 0.3$ mIU/L (dependent on type of assay used) and/or elevated leuprolide-stimulated LH level $> 3.3 - 5$ IU/L (dependent on type of assay used);
 - b. Difference between bone age and chronological age was > 1 year (bone age-chronological age);

- c. Age at onset of secondary sex characteristics (i or ii):
 - i. Female: < 8 years;
 - ii. Male: < 9 years;
 2. Request is for Supprelin LA;
 3. Prescribed by or in consultation with a pediatric endocrinologist;
 4. Member meets one of the following age requirements (a or b):
 - a. Female: 2 - 11 years;
 - b. Male: 2 - 12 years;
 5. Dose does not exceed 50 mg per 12 months (one implant per year).
- Approval duration: 12 months**

C. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: HIM.PA.33 for health insurance marketplace and CP.PMN.255 for Medicaid; or
 - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: HIM.PA.103 for health insurance marketplace and CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: HIM.PA.154 for health insurance marketplace and CP.PMN.53 for Medicaid.

II. Continued Therapy

A. Prostate Cancer (must meet all):

1. Currently receiving medication via Centene benefit, or documentation supports that member is currently receiving Vantas for prostate cancer and has received this medication for at least 30 days;
2. Request is for Vantas;
3. Member is responding positively to therapy;
4. If request is for a dose increase, request meets one of the following (a or b):*
 - a. New dose does not exceed 50 mg per 12 months (one implant per year);
 - b. New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Prescribed regimen must be FDA-approved or recommended by NCCN*

Approval duration: 12 months

B. Central Precocious Puberty (must meet all):

1. Member meets one of the following (a or b):
 - a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;

- b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B*);
2. Request is for Supprelin LA;
3. Member is responding positively to therapy as evidenced by, including but not limited to, improvement in any of the following parameters: decreased growth velocity, cessation of menses, softening of breast tissue or testes, arrested pubertal progression;
4. Member meets one of the following age requirements (a or b):
 - a. Female: ≤ 11 years;
 - b. Male: ≤ 12 years;
5. If request is for a dose increase, new dose does not exceed 50 mg per 12 months (one implant per year).

Approval duration: 12 months

C. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: HIM.PA.33 for health insurance marketplace and CP.PMN.255 for Medicaid; or
 - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: HIM.PA.103 for health insurance marketplace and CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: HIM.PA.154 for health insurance marketplace and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.PMN.53 for Medicaid and HIM-Medical Benefit, or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

CPP: central precocious puberty

FDA: Food and Drug Administration

GnRH: gonadotropin-releasing hormone

LH: luteinizing hormone

NCCN: National Comprehensive Cancer
Network

Appendix B: Therapeutic Alternatives

Not applicable

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s): hypersensitivity to GnRH, GnRH agonist analogs; pregnancy
- Boxed warning(s): none reported

V. Dosage and Administration

Drug Name	Indication	Dosing Regimen	Maximum Dose
Histrelin acetate (Supprelin LA)	CPP	1 implant (50 mg) SC for 12 months	1 implant per 12 months
Histrelin acetate (Vantas)	Prostate cancer - palliative therapy	1 implant (50 mg) SC for 12 months	1 implant per 12 months

VI. Product Availability

Drug Name	Availability
Histrelin acetate (Supprelin LA)	Implant: 50 mg (approximately 65 mcg histrelin acetate per day over 12 months)
Histrelin acetate (Vantas)	Implant: 50 mg (approximately 50 mcg histrelin acetate per day over 12 months)

VII. References

1. Vantas Prescribing Information. Malvern, PA: Endo Pharmaceuticals Solutions, Inc.; December 2020. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021732s023lbl.pdf. Accessed July 28, 2022.
2. Supprelin LA Prescribing Information. Malvern, PA: Endo Pharmaceuticals Solutions, Inc.; April 2022. Available at www.supprelinla.com. Accessed July 28, 2022.
3. National Comprehensive Cancer Network Drugs and Biologics Compendium. Available at nccn.org. Accessed July 28, 2022.
4. National Comprehensive Cancer Network. Prostate Cancer Version 4.2022. Available at https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed July 28, 2022.
5. Kaplowitz P, Bloch C. Evaluation and referral of children with signs of early puberty. *Pediatrics*. 2016; 137(1): e20153732.
6. Carel JC, Eugster EA, Rogol A, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. *Pediatrics*. 2009;123(4):e752. Epub 2009 Mar 30.
7. Krishna KB, Fuqua JS, Rogol AD, et al. Use of gonadotropin-releasing hormone analogs in children: update by an International Consortium. *Horm Res Paediatr* 2019;91:357–372. DOI: 10.1159/000501336.
8. Silverman LA, Neely EK, Kletter GB, et al. Long-term continuous suppression with once-yearly histrelin subcutaneous implants for the treatment of central precocious puberty: a final report of a phase 3 multicenter trial. *J Clin Endocrinol Metab*. 2015;100(6):2354-2363.

Coding Implications

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPSC Codes	Description
J9225	Histrelin implant (Vantas), 50 mg
J9226	Histrelin implant (Supprelin LA) 50 mg
J1675	Injection, histrelin acetate, 10 micrograms

Reviews, Revisions, and Approvals	Date	P&T Approval Date
4Q 2018 annual review: no significant changes; added HIM-Medical; for oncology, summarized NCCN and FDA-approved uses for improved clarity (limited to diagnosis); specialist involvement in care and continuation of care added; references reviewed and updated.	08.07.18	11.18
4Q 2019 annual review: prostate cancer – removed the following as there is no preferred product among the GnRH agonists and the requirement is not included for the CPP indication which is similarly for an implant formulation: “Documentation showing a history of ≥ 3 months of gonadotropin-releasing hormone (GnRH) agonist injections that were effective and well tolerated”, added urologist specialist option; references reviewed and updated.	08.01.19	11.19
4Q 2020 annual review: no significant changes; references reviewed and updated.	08.11.20	11.20
4Q 2021 annual review: no significant changes; references reviewed and updated.	07.14.21	11.21
4Q 2022 annual review: no significant changes; references reviewed and updated. Template changes applied to other diagnoses/indications and continued therapy section.	07.28.22	11.22

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy,

contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:

For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene[®] and Centene Corporation[®] are registered trademarks exclusively owned by Centene Corporation.